Pain Program – Genentech Collaboration

Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics

We will collaborate with Genentech on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics for development and commercialization of products. Xenon is eligible for payments from the partnership totaling up to $646 million for multiple products and indications, and royalties on sales of products resulting from the collaboration.

This alliance highlights the keen interest in our genetic approach to drug development and in our translational R&D capabilities.